Skip to main content

Articles

Once Off Patent, Imatinib Will Be the Most Cost-Effective Treatment for Newly Diagnosed CML
Read More
High Cancer Drug Prices Hurt Patients
Read More
Stem-Cell Mobilization More Cost-Effective with Plerixafor
Read More
Financial Toxicity Impacts Treatment Adherence
Read More
American-Style Capitalism Drives Drug Development: Cancer Therapies Targeting Small Subpopulations Dictate Prices
Read More
FDA Approvals
The Hematology Pipeline Is Abundant
Read More
Value and Cost-Effectiveness Analyses Should Be Included in Reimbursement Decisions
Read More
Leukemia, Oncology
Psychological Distress and Financial Burden Impact Adherence to CML Treatment
Read More
FDA Approvals, Payers' Guide
The Sixth Annual Payers’ Guide to New FDA Approvals
Read More
Introduction, Payers' Guide
New FDA Drug Approvals Hit an 18-Year High in 2014
Read More
Page 135 of 244
Results 1341 - 1350 of 2436